RECOVER/ARVIN-GOODS
15.2.2024 13:01:29 CET | Business Wire | Press release
Arvin Goods, the Seattle-based responsible apparel brand, has announced the release of its latest sock collection, crafted from Recover™ recycled cotton fiber. Since launching in 2019, the company has been at the forefront of sustainable fashion and is one of the few brands in the market utilizing recycled materials for its entire collection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215745837/en/
(Photo: Arvin Goods)
The latest launch features crew socks made from 79% recycled materials, including 43% recycled polyester and 36% Recover recycled cotton fiber. Recover’s proprietary recycled fiber is one of the lowest-impact fibers available in the market, significantly reducing the carbon and water footprint of the apparel supply chain. Manufacturing just one pair of Arvin Goods socks made with 36% Recover fiber saves up to 18 gallons of water compared to a pair made with conventional cotton.
Boris Mercier, SVP Marketing at Recover, said, “Our ongoing work with Arvin Goods was born out of a shared belief in the importance of circular fashion that never sacrifices quality, feel, or style. As the ingredient brand of reference in recycled cotton, we aim to educate consumers to make more conscious choices and accelerate the adoption of sustainable initiatives within the casual wear segment.”
For each pair of socks, responsibility is the core of Arvin’s approach to the design, manufacturing, and distribution. As well as using low-impact impact recycled materials, responsibility was also prioritized in the value chain. Thanks to Recover’s strategic partnership with Ferre Yarns, based locally in Alicante, Spain the impact of transportation was also minimized.
Dustin Winegardner, Managing Partner at Arvin Goods, commented, “We have been working with Recover™, and the Ferre family of yarns since the beginning of Arvin Goods. Making it official like this and stamping the R on our packaging is an exciting step for our brand. Being able to source materials in Spain, and manufacture nearby in Portugal moves us further in our mission to deliver The Cleanest Basics on the Planet.”
Paqui Ferre, Sales and Marketing Director at Ferre, also commented, “Ferre has been working with Arvin Goods since the beginning of its history. In a clear commitment to sustainability, Arvin makes products using our most iconic yarn, FBlue. Consistent with our brand vision, FBLUE 100% recycled yarns deliver the perfect combination of circularity, performance, and color accuracy. A blend with Recover recycled cotton that answers the global call for sustainably sourced yarns while providing inspiring colors for Arvin Goods products.”
The new collection not only exemplifies Arvin Goods' sustainable ethos but also provides customers with a stylish and comfortable choice for everyday wear. The brand continues to set a new standard for low-impact fashion, encouraging consumers to make conscious choices that positively impact the planet.
The Arvin Goods recycled fiber collection starts at $12 USD and is available to purchase through their website.
Find out more about the collaboration here.
About Arvin Goods
Established in 2019 Arvin Goods has set out to help clean up a dirty industry. By utilizing recycled base materials and minimizing the movement of materials in manufacturing they are reducing the impact of one of the world's most consumed categories. Basics.
Arvin Goods produces comfortable on-trend products, that also happen to be the lowest-impact socks in the marketplace. Arvin Goods is based in Seattle, Washington USA.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends at scale. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
About Ferre
Ferre is a fourth-generation family business with a history of more than 75 years innovating the manufacture of high-quality recycled yarns. Our open-end spin factory is based in Banyeres de Mariola (Alicante), Spain and the company, founded in 1947, has been innovating the cotton recycled spinning process ever since.
We work every day to improve our products and help our customers to maximize the full potential of our low-impact yarns, always guided for the commitment of making more with less. Ferre yarns stand out for their quality and low-impact products, bringing accurate and beautiful colours to the sustainable fashion value chain.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215745837/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
